Canada has just bought 20,000 doses of Bavarian Nordic’s vaccine with an option to buy an additional 180,000, but the market potential for the country is 10 million doses, Bavarian CEO Anders Hedegaard tells Medwatch. Meanwhile, the company has begun negotiations with a number of other countries, and they hope to start delivering the vaccine to European countries in the near future.
“There is a lot of money in this order. But there is also a positive signal value, in that they place the order prior to approval. To us that means they view Imvamune in a positive light, although there are no guarantees,” he points out and adds: